CITIC Securities: The pharmaceutical industry is showing signs of improvement; actively monitor the development of cutting-edge technologies.

China's pharmaceutical industry is gradually gaining global competitiveness. Over the long term, the sector is expected to produce globally leading companies, but investors should also fully anticipate the challenges associated with international expansion—this will inevitably be a long and arduous process.

Zhitong FinanceJun 15 10:15

CITIC Securities: Foot traffic at physical pharmacies is being reallocated; 2026 will be a pivotal year for pharmacy transformation and restructuring.

2025 marks the inaugural year for pharmacy restructuring and transformation, while 2026 will be a pivotal year for large-scale pharmacy transformation and restructuring.

Zhitong FinanceJun 12 09:55

Essential Demand? Pharmaceutical Distribution Races Toward 'Unmanned' Operations

Guancha SyndicateMay 30 11:06

Zhongtai Securities: Pharmacy sector profits in Q1 2026 continued double-digit year-over-year growth; monitor the accelerated recovery trend in Q2 as the high flu-related base effect from the prior year dissipates.

In mid-May 2026, the National Healthcare Security Administration held talks with certain offline pharmacy chain companies. Amid mounting pressure on consumer spending and capital outflows into stronger-performing sectors, share prices of offline pharmacies have remained under significant pressure recently.

Zhitong FinanceMay 27 07:28

Yixintang (002727.SZ) 2025 Annual Profit Distribution: RMB 2 per 10 shares

Gelonghui, May 22 — Yixintang Pharmacy Co., Ltd. (SZSE: 002727) announced its 2025 Annual Profit Distribution Implementation Notice. The profit distribution plan approved by the company’s 2025 annual shareholders’ meeting is as follows: based on the total number of shares outstanding on the record date for the 2025 profit distribution, excluding shares held in the company’s repurchase account (as of the date of this announcement, the company holds 11,475,900 shares in its dedicated repurchase securities account), the company will distribute a cash dividend of RMB 2.00 (tax inclusive) per 10 shares to all shareholders. No bonus shares will be issued, and no capital reserve will be converted into share capital. The total expected cash dividend amounts to RMB 114.8

Gelonghui FinanceMay 22 17:23

Research Report Insights | Orient Securities: Reiterates 'Buy' Rating for Yixintang, Store Optimization Drives Non-Drug Growth and Profit Improvement

The research report from Orient Securities points out that the optimization of Yixintang's stores has driven non-pharmaceutical growth and improved profitability. The company is expected to achieve a net profit attributable to shareholders of 260 million yuan (+130.8%) in 2025, and 180 million yuan (+9.8%) in Q1 2026. Revenue remains under pressure, but profitability continues to improve. The core market has been deeply covered, and store optimization is on track. Notably, the value co-creation project fully implemented in 2025 has significantly improved key operating indicators for hundreds of stores, expanded across multiple regions, and is steadily increasing its coverage. Further breakthroughs are anticipated in model building and replication promotion, with an even broader rollout expected in 2026.

Gelonghui FinanceMay 18 17:40 · Ratings